FDA-cleared profile

Sonic DL

GE Medical Systems, LLC · MRI · FDA-cleared (510(k))

Authorized purpose: Sonic DL is optional integrated GE MRI reconstruction for supported 2D cardiac cine and 3D fast-spin-echo or gradient-echo acquisitions at 1.5T, 3T, and 7T for all ages and anatomies; very high acceleration can reduce small low-contrast lesion detectability.

Clinical role
Integrated MR image reconstruction that reduces noise or artifacts before routine professional interpretation.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: At very high acceleration factors, there may be a slight degradation in image quality affecting detectability for small low contrast lesions; clinicians should use their best judgement based on the patient and clinical scenario.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Sonic DL is optional integrated GE MRI reconstruction for supported 2D cardiac cine and 3D fast-spin-echo or gradient-echo acquisitions at 1.5T, 3T, and 7T for all ages and anatomies; very high acceleration can reduce small low-contrast lesion detectability.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Highly under-sampled MR data from GE HealthCare 1.5T, 3.0T, and 7.0T MR systems.
  • Who uses it?Intended users: Clinicians.
  • What does the software produce?Output: Reconstructed MR images appropriate for diagnostic use.
  • What is its most important limitation?Key limitation: At very high acceleration factors, there may be a slight degradation in image quality affecting detectability for small low contrast lesions; clinicians should use their best judgement based on the patient and clinical scenario.

Clinical takeaway. Clinical role: Sonic DL is optional integrated GE MRI reconstruction for supported 2D cardiac cine and 3D fast-spin-echo or gradient-echo acquisitions at 1.5T, 3T, and 7T for all ages and anatomies; very high acceleration can reduce small low-contrast lesion detectability.

Evidence takeaway. Evidence from the reviewed source record: K243667 reports digital-reference-object, phantom, and clinical testing. Acceleration up to 12 was evaluated; very high acceleration can slightly degrade image quality and small low-contrast lesion detectability.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Sonic DL is optional integrated GE MRI reconstruction for supported 2D cardiac cine and 3D fast-spin-echo or gradient-echo acquisitions at 1.5T, 3T, and 7T for all ages and anatomies; very high acceleration can reduce small low-contrast lesion detectability.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Integrated MR image reconstruction that reduces noise or artifacts before routine professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Highly under-sampled MR data from GE HealthCare 1.5T, 3.0T, and 7.0T MR systems.
  • Exact FDA submission
  • Checked 2026-09-19

The packet states that Sonic DL reconstructs MR images from highly under-sampled data and lists the compatible GE HealthCare field strengths; it does not establish the dossier's coil and input-quality wording.

Output and clinician action
Reconstructed MR images appropriate for diagnostic use.
  • Exact FDA submission
  • Checked 2026-09-19

The packet directly states that Sonic DL reconstructs MR images and that the collected performance data support image quality appropriate for diagnostic use; archival and review claims are not stated.

Care setting
Hospital and outpatient MRI departments using compatible GE MRI systems.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Clinicians.
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet refers to clinicians making the acceleration tradeoff; it does not identify MRI technologists as an intended-user class.

Limitations
At very high acceleration factors, there may be a slight degradation in image quality affecting detectability for small low contrast lesions; clinicians should use their best judgement based on the patient and clinical scenario.
  • Exact FDA submission
  • Checked 2026-09-19

This replaces the dossier's broader scanner, coil, sequence, and input-quality claim with the exact packet's stated acceleration and low-contrast limitation.

Evidence summary
K243667 reports digital-reference-object, phantom, and clinical testing. Acceleration up to 12 was evaluated; very high acceleration can slightly degrade image quality and small low-contrast lesion detectability.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K243667 reports digital-reference-object, phantom, and clinical testing. Acceleration up to 12 was evaluated; very high acceleration can slightly degrade image quality and small low-contrast lesion detectability.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Maximum evaluated acceleration factor

12 factor

  • EndpointSupported Sonic DL acceleration
  • PopulationSonic DL
  • Tested versionSonic DL Cine and Sonic DL 3D release cleared in K243667

K243667 FDA performance package for Sonic DL

  • DesignManufacturer nonclinical phantom and clinical image-quality validation
  • PopulationSupported cardiac cine and 3D MRI acquisitions across cleared field strengths and anatomies
  • Scopeexact submission
  • Tested versionSonic DL Cine and Sonic DL 3D release cleared in K243667
  • IndependenceSponsor or vendor study

K243667

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K243667 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Highly under-sampled MR data from GE HealthCare 1.5T, 3.0T, and 7.0T MR systems.

    Scope: Exact FDA submission. The packet states that Sonic DL reconstructs MR images from highly under-sampled data and lists the compatible GE HealthCare field strengths; it does not establish the dossier's coil and input-quality wording.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K243667: Sonic DL

  2. Routing

    Source context, not route validation: Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K243667: Sonic DL · GE HealthCare Sonic DL announcement

  3. AI processing

    Source context, not route validation: Licensed software integrated into supported GE MRI scanner configurations.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K243667: Sonic DL · GE HealthCare Sonic DL announcement

  4. Returned objects

    Source context, not route validation: Reconstructed MR images appropriate for diagnostic use.

    Scope: Exact FDA submission. The packet directly states that Sonic DL reconstructs MR images and that the collected performance data support image quality appropriate for diagnostic use; archival and review claims are not stated.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K243667: Sonic DL

  5. Viewer/worklist/report

    Unresolved route: Reconstructed MR images appropriate for diagnostic use.

    Scope: Exact FDA submission. The packet directly states that Sonic DL reconstructs MR images and that the collected performance data support image quality appropriate for diagnostic use; archival and review claims are not stated.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K243667: Sonic DL

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Licensed software integrated into supported GE MRI scanner configurations.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.
  • Exact FDA submission
  • Checked 2026-09-03
Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified mri technologists and interpreting physicians. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K243667 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Integrated scanner reconstruction followed by normal DICOM export; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Performance depends on supported scanner, field strength, coil, sequence, anatomy, acceleration, and input quality; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243667
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-06-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
7Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 7 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 7 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA K243667: Sonic DL

    U.S. Food and Drug Administration - Published 2025-06-05 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, evidenceSummary, intendedUsers, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GE HealthCare Sonic DL announcement

    GE HealthCare - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  8. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K243667 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K220589

MAGNETOM Skyra Fit

Siemens Medical Solutions USA, Inc.

Authorized purpose: MAGNETOM Skyra Fit with syngo MR XA50A is a 3T system for broad head, body, and extremity MRI; this release includes TSE motion correction and automatic breast-biopsy fiducial detection.

Modality
MRI
Anatomy
Multi-region
Decision
2022-05-13
FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history